Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 13Liver Neoplasms 3Carcinoma, Renal Cell 3Glioblastoma 2Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Pediatric Solid Tumors 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Diseases 1Gliosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Brain Neoplasms 1Advanced Cancers 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

X-Rays 1Vorinostat 1Sorafenib 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1Curcumin 1Cetuximab 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Advanced Cancers × Sorafenib × Clear all
NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡